Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2023-02-23 00:00:00 ET · period of report 2023-02-21 · accession 0001162194-23-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-23 | 2023-02-21 | LAB | JOG VIKRAM | CFO | M - OptEx | $0.00 | +74.4K | 246.3K | +43% | $0 |
| D | 2023-02-23 | 2023-02-21 | LAB | JOG VIKRAM | CFO | F - Tax | $2.03 | -28.7K | 217.6K | -12% | -$58.3K |
| DM | 2023-02-23 | 2023-02-21 | LAB | JOG VIKRAM | CFO | M - OptEx | $0.00 | -71.3K | 0 | -100% | $0 |
| D | 2023-02-23 | 2023-02-21 | LAB | JOG VIKRAM | CFO | A - Grant | $0.00 | -3,130 | 28.2K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-21 | M | A | 2,391 | $0.00 | 243,199 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-21 | M | A | 2,238 | $0.00 | 240,808 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-21 | M | A | 16,666 | $0.00 | 238,570 | D | — | — | |
| 4 | Common | Common Stock | 2023-02-21 | M | A | 50,000 | $0.00 | 221,904 | D | — | — | |
| 5 | Common | Common Stock | 2023-02-21 | F | D | 28,707 | $2.03 | 217,622 | D | — | — | |
| 6 | Common | Common Stock | 2023-02-21 | M | A | 3,130 | $0.00 | 246,329 | D | — | — | |
| 7 | Derivative | Restricted Stock Units | 2023-02-21 | M | D | 50,000 | $0.00 | 0 | D | — · — to — | 50,000 Common Stock | (F2) Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. (F3) The Restricted Stock Units vest in full on February 20, 2023 or the date the Reporting Person's employment with the Company is terminated involuntarily without "cause." |
| 8 | Derivative | Restricted Stock Units | 2023-02-21 | M | D | 16,666 | $0.00 | 183,334 | D | — · — to — | 16,666 Common Stock | (F2) Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. (F4) On December 20, 2022, the Reporting Person was granted 200,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023. |
| 9 | Derivative | Restricted Stock Units | 2023-02-21 | A | D | 3,130 | $0.00 | 28,176 | D | — · — to — | 3,130 Common Stock | (F2) Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. (F7) On April 20, 2021, the Reporting Person was granted 50,089 Restricted Stock Units vesting as to 1/4 of the total number of shares on May 20, 2022, and as to 1/16th of the total number of shares each quarter thereafter. |
| 10 | Derivative | Restricted Stock Units | 2023-02-21 | M | D | 2,391 | $0.00 | 9,563 | D | — · — to — | 2,391 Common Stock | (F2) Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. (F6) On March 10, 2020, the Reporting Person was granted 38,250 Restricted Stock Units vesting as to 1/4th of the underlying shares on February 20, 2021, and as to 1/16th of the total number of shares each quarter thereafter. |
| 11 | Derivative | Restricted Stock Units | 2023-02-21 | M | D | 2,238 | $0.00 | 0 | D | — · — to — | 2,238 Common Stock | (F2) Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. (F5) On February 19, 2019, the Reporting Person was granted 35,787 Restricted Stock Units vesting as to 1/4th of the total number of shares on February 20, 2020, and as to 1/16th of the total number of shares each quarter thereafter. |